AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.9076
-0.0824 (-8.32%)
Feb 27, 2026, 4:00 PM EST - Market closed
AIM ImmunoTech Employees
As of December 31, 2024, AIM ImmunoTech had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 5 or -17.86% compared to the previous year.
Employees
23
Change (1Y)
-5
Growth (1Y)
-17.86%
Revenue / Employee
$4,870
Profits / Employee
-$684,783
Market Cap
3.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | 23 | -3 | -11.54% | 21 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| Jaguar Health | 49 |
| GeoVax Labs | 17 |
| Indaptus Therapeutics | 7 |
| Galmed Pharmaceuticals | 6 |
| Acurx Pharmaceuticals | 4 |
| GRI Bio | 4 |
| 60 Degrees Pharmaceuticals | 3 |
AIM News
- 1 day ago - AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - GlobeNewsWire
- 5 days ago - AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 16 days ago - CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewsWire
- 17 days ago - AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewsWire
- 19 days ago - Aimia Inc. (AIM:CA) M&A Call Transcript - Seeking Alpha
- 22 days ago - AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire
- 23 days ago - AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewsWire